Some treatments include mast-cell stabilizers to control their access to inflamed tissue and consequent cytokine production (IL-1, IL-6 and TNF-a) [46]; moreover, it has been suggested that treatment for idiopathic pulmonary fibrosis could benefit patients with PC19-PF [47]. Here, IL6 is linked to idiopathic pulmonary fibrosis.